Rocket Pharmaceuticals stock rises on FDA approval

Rocket Pharmaceuticals experienced a significant stock price increase following the U.S. Food and Drug Administration's (FDA) approval of its gene therapy. This regulatory milestone validates the company's research and development efforts, paving the way for commercialization. The approval is expected to boost investor confidence and potentially lead to substantial revenue growth for the company in the coming years.